U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Last Updated: 01.07.2025 13:42

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has ap… [+11553 chars]

June 9, 2025 3:11 pm ET

RAHWAY, N.J.--(BUSINESS WIRE)--

‘How to Train Your Dragon’ soars in box office debut with $83.7 million, beating ‘Lilo & Stitch’ - AP News